StockNews.com Downgrades Aspira Women’s Health (NASDAQ:AWH) to Sell

StockNews.com lowered shares of Aspira Women’s Health (NASDAQ:AWH) from a hold rating to a sell rating in a research note released on Thursday morning.

Separately, Alliance Global Partners dropped their target price on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 1.1 %

NASDAQ:AWH opened at $0.84 on Thursday. Aspira Women’s Health has a fifty-two week low of $0.81 and a fifty-two week high of $6.59. The company has a 50 day moving average price of $1.19 and a 200 day moving average price of $2.25.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $2.60 million. During the same quarter in the prior year, the business earned ($0.28) earnings per share. On average, sell-side analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.73% of Aspira Women’s Health worth $732,000 at the end of the most recent quarter. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.